391 related articles for article (PubMed ID: 31838163)
1. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review.
Bellan M; Patrucco F; Barone-Adesi F; Gavelli F; Castello LM; Nerviani A; Andreoli L; Cavagna L; Pirisi M; Sainaghi PP
Autoimmun Rev; 2020 Feb; 19(2):102453. PubMed ID: 31838163
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
5. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Wang Y; Li L
Int J Rheum Dis; 2023 Feb; 26(2):225-235. PubMed ID: 36378118
[TBL] [Abstract][Full Text] [Related]
8. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion.
Liossis SC; Bounia CA
Front Med (Lausanne); 2022; 9():937561. PubMed ID: 35847798
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
10. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
[TBL] [Abstract][Full Text] [Related]
11. Connective tissue disease--associated interstitial lung disease: an underreported cause of interstitial lung disease in Sub-Saharan Africa.
Olaosebikan H; Adeyeye O; Akintayo R; Akpabio A; Adenitan A; Adelowo O; Ojo O; Abimbola FO
Clin Rheumatol; 2021 Sep; 40(9):3455-3460. PubMed ID: 32803569
[TBL] [Abstract][Full Text] [Related]
12. Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
Zhao Y; Gao Y; Petnak T; Cheungpasitporn W; Thongprayoon C; Zhang X; Moua T
Respir Res; 2022 Jun; 23(1):164. PubMed ID: 35729565
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.
Sharp C; McCabe M; Dodds N; Edey A; Mayers L; Adamali H; Millar AB; Gunawardena H
Rheumatology (Oxford); 2016 Jul; 55(7):1318-24. PubMed ID: 27060110
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
Mittoo S; Jacob T; Craig A; Bshouty Z
Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases.
Vicente-Rabaneda EF; Serra López-Matencio JM; Ancochea J; Blanco R; González-Gay MÁ; Castañeda S
Expert Opin Drug Saf; 2022 Mar; 21(3):311-333. PubMed ID: 34433372
[TBL] [Abstract][Full Text] [Related]
16. Comparison of characteristics of connective tissue disease-associated interstitial lung diseases, undifferentiated connective tissue disease-associated interstitial lung diseases, and idiopathic pulmonary fibrosis in Chinese Han population: a retrospective study.
Pan L; Liu Y; Sun R; Fan M; Shi G
Clin Dev Immunol; 2013; 2013():121578. PubMed ID: 24171031
[TBL] [Abstract][Full Text] [Related]
17. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
18. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study.
Oguz EO; Kucuksahin O; Turgay M; Yildizgoren MT; Ates A; Demir N; Kumbasar OO; Kinikli G; Duzgun N
Clin Rheumatol; 2016 Mar; 35(3):663-6. PubMed ID: 26758437
[TBL] [Abstract][Full Text] [Related]
19. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
20. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).
Jee AS; Corte TJ
Drugs; 2019 Sep; 79(14):1511-1528. PubMed ID: 31399860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
